Excellent animal proof of
concept studies with multiple
mechanism of actions (MOAs)

FHL-301 is a repurposed drug, a synthetic agonist of PPAR-Alpha helps in reducing inflammation and glial activation.

FHL-801 is a neutralizing antibody which protects dopaminergic neurons and reduces inflammation by inhibiting RANTES and eotaxin.

FHL-701 is a monoclonal antibody which inhibits an IL-12 subtype and has been shown to reduce the amyloid plaque load in the hippocampus, a significant marker for Alzheimer’s Disease.

FHL-601 is a repurposed drug which prevents damage of dopaminergic neurons by blocking CCR5 receptor and preventing T-cell infiltration, endorsed by anti-inflammatory mechanism of action.

FHL-501 is a novel peptide which inhibits the NK-FB pathway to reduce inflammation and protect dopaminergic neurons.

FHL-401 is a novel peptide which protects the dopaminergic neurons by blocking the spread of synuclein associated pathology and inflammation by interfering with TLR-2- MyD88 signals.

FHL-201 is another small molecule derived from natural ingredients and basically an endogenous ligand of PPAR-Alpha works by restoring striatal neuro transmitters and motor functions.

FHL-101 is a small molecule derived from natural ingredients that promotes dopaminergic activity by maintaining sustained levels of proteins and neurotransmitters necessary for protection of dopaminergic neurons.